|
Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC
Aeterna Zentaris Inc. today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131.
More... |
| All times are GMT -7. The time now is 03:51 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021